企業(yè)發(fā)布
首頁(yè) > 企業(yè)發(fā)布 > 詳細(xì)內(nèi)容
西安天美生物科技宣布上半年的收入和凈利潤(rùn)創(chuàng)下新高
2021/8/18 10:01:15 來(lái)源:中國(guó)企業(yè)新聞網(wǎng)
導(dǎo)言:西安天美生物科技股份有限公司今天宣布其截至2021年3月31日的6個(gè)月的半年度財(cái)務(wù)業(yè)績(jī)。
西安天美生物科技股份有限公司今天宣布其截至2021年3月31日的6個(gè)月的半年度財(cái)務(wù)業(yè)績(jī)。
2021年上半年財(cái)務(wù)亮點(diǎn)
管理層討論
“我們創(chuàng)新高的收入和收益的加速增長(zhǎng)是我們作為上市公司首次公布業(yè)績(jī)的很好的答卷,并為天美作為上市公司起了一個(gè)良好的開(kāi)端,”天美生物的董事長(zhǎng)兼CEO胡永衛(wèi)表示,“我們的行業(yè)知名品牌與優(yōu)質(zhì)產(chǎn)品相結(jié)合,為我們的客戶帶來(lái)了很高的價(jià)值主張,并為我們?cè)谶@個(gè)市場(chǎng)需求增長(zhǎng)的時(shí)期提升市場(chǎng)份額提供了堅(jiān)實(shí)的基礎(chǔ)。今年到目前為止,我們?cè)谛聵I(yè)務(wù)上取得的成果以及正在開(kāi)發(fā)中的產(chǎn)品銷(xiāo)售的趨勢(shì)也令我感到鼓舞。我們將繼續(xù)優(yōu)化我們的銷(xiāo)售策略,著重大型企業(yè)客戶,并降低我們的制造成本,以支持可持續(xù)的長(zhǎng)期盈利能力。我要感謝我們辛勤工作的團(tuán)隊(duì),公司的成功離不開(kāi)他們的不懈努力,以及我們忠實(shí)的客戶對(duì)我們的信任。我們?cè)谟耖T(mén)工廠的擴(kuò)張的時(shí)機(jī)非常好。目前,市場(chǎng)對(duì)我們產(chǎn)品需求旺盛,產(chǎn)能的提升提高,將為公司銷(xiāo)售增長(zhǎng)提供保障,更好滿足當(dāng)前市場(chǎng)客戶的需求。而公司新生產(chǎn)基地可以幫助我們實(shí)現(xiàn)這一目標(biāo)。我們相信,我們的獨(dú)有的技術(shù)、商業(yè)模式和戰(zhàn)略將使我們能夠獲得更多的市場(chǎng)份額,并保持增長(zhǎng)勢(shì)頭。”
2021上半年產(chǎn)品(按類別)與上年相比增長(zhǎng)總結(jié):
|
收入增加(減少) |
毛利潤(rùn)增加(減少) |
香料原料 |
133.0% |
226.9% |
膳食補(bǔ)充劑(固體飲料) |
338.4% |
306.0% |
生物活性食品原料 |
(69.7%) |
(79.0%) |
香料原料
膳食補(bǔ)充劑(固體飲料)
生物活性食品原料
管理費(fèi)用從截至2020年3月31日的六個(gè)月的811,799美元減少到2021年同期的679,635美元,減少了132,164美元,或大約16.3%,主要是由于截至2021年3月31日的六個(gè)月內(nèi)專業(yè)咨詢服務(wù)費(fèi)用減少了197,327美元。公司在截至2020年3月31日的六個(gè)月內(nèi)產(chǎn)生了較高的咨詢服務(wù)費(fèi)用和較高的審計(jì)費(fèi)用。
政府補(bǔ)貼以補(bǔ)貼形式獲得并確認(rèn)為其他營(yíng)業(yè)收入,在截至2021年3月31日和2020年3月31日的六個(gè)月里,總額分別為446,910美元和332,418美元。
凈利潤(rùn)從截至2020年3月31日的六個(gè)月的160萬(wàn)美元增加到2021年同期的230萬(wàn)美元。
經(jīng)營(yíng)活動(dòng)產(chǎn)生的凈現(xiàn)金在截至2021年3月31日的六個(gè)月期間為200萬(wàn)美元,2020年同期為50萬(wàn)美元。
稀釋后每股收益(“EPS”)為0.40美元,2020年同期為0.30美元。
我們鼓勵(lì)投資者查閱公司完整的財(cái)務(wù)報(bào)表和相關(guān)的披露資料,以了解更多信息。這些材料可在https://www.sec.gov/edgar/browse/?CIK=1816815&owner=exclude.中查閱。
報(bào)告期后事件
投資者電話會(huì)議和網(wǎng)絡(luò)直播
討論公司2021年上半年財(cái)務(wù)業(yè)績(jī)的網(wǎng)絡(luò)直播將于2021年8月17日美國(guó)東部時(shí)間上午8:30開(kāi)始。網(wǎng)絡(luò)直播和相關(guān)PPT的獲取可以訪問(wèn)公司的投資者網(wǎng)站 https://ir.bnlus.com/events-presentations/。對(duì)于無(wú)法觀看網(wǎng)絡(luò)直播的人,在活動(dòng)結(jié)束后公司將在網(wǎng)站上提供錄制版本。
預(yù)先登記:https://dpregister.com/sreg/10159604/ec6c783af0
預(yù)先登記的呼叫者將得到一個(gè)會(huì)議密碼和獨(dú)有PIN碼,可以立即進(jìn)入電話會(huì)議并繞過(guò)接線員。與會(huì)者可以在任何時(shí)候進(jìn)行預(yù)先登記,包括在電話會(huì)議開(kāi)始后。
無(wú)法互聯(lián)網(wǎng)接入或無(wú)法預(yù)先登記的人可以通過(guò)以下電話撥入:
美國(guó)免費(fèi)電話:1-866-777-2509
國(guó)際收費(fèi)電話:1-412-317-5413
西安天美生物科技股份有限公司
西安天美生物專注于膳食營(yíng)養(yǎng)補(bǔ)充劑的生物活性成分的生產(chǎn),如為食品制造商提供天然益生元;個(gè)人護(hù)理成分的生產(chǎn),如為香水香料制造商提供從植物來(lái)源的香料原料,天然復(fù)配膳食補(bǔ)充劑生產(chǎn),如固體飲料。欲了解更多信息,請(qǐng)?jiān)L問(wèn)公司網(wǎng)站:www.bnlus.com.
安全港聲明
本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關(guān)公司計(jì)劃、目標(biāo)、戰(zhàn)略、未來(lái)事件或業(yè)績(jī)的聲明,以及其他假設(shè)和不包含歷史事件的聲明。當(dāng)公司使用諸如“可能”、“將”、“打算”、“應(yīng)該”、“相信”、“期望”、“預(yù)期”、“計(jì)劃”、“估計(jì)”等或其他類似的表達(dá)方式,并不與歷史事件有關(guān),就是在做前瞻性聲明。前瞻性聲明不是對(duì)公司未來(lái)業(yè)績(jī)的保證,涉及風(fēng)險(xiǎn)和不確定性,可能會(huì)導(dǎo)致實(shí)際結(jié)果與前瞻性聲明中討論的公司預(yù)期有實(shí)質(zhì)性的差異。這些陳述受不確定性和風(fēng)險(xiǎn)因素的印象,包括但不限于:公司的目標(biāo)和戰(zhàn)略、公司的未來(lái)業(yè)務(wù)發(fā)展、公司產(chǎn)品和服務(wù)的需求、技術(shù)的變化、經(jīng)濟(jì)狀況、中國(guó)天然健康和個(gè)人護(hù)理行業(yè)的發(fā)展及公司希望發(fā)展的其他國(guó)際市場(chǎng)、聲譽(yù)和品牌、競(jìng)爭(zhēng)和定價(jià)的影響、政府法規(guī)、中國(guó)及公司希望發(fā)展的其他國(guó)際市場(chǎng)的經(jīng)濟(jì)和商業(yè)狀況的變動(dòng),以及與上述任何情況相關(guān)的假設(shè)和公司提交給SEC報(bào)告中所陳述的其他風(fēng)險(xiǎn)。因此,我們提醒投資者不要過(guò)分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素,這些文件可在www.sec.gov上查閱。公司不承擔(dān)公開(kāi)修訂本聲明日期之后出現(xiàn)的事件或情況的前瞻性聲明的義務(wù)。
更多信息,請(qǐng)聯(lián)系:
In the United States: |
In China: |
Maggie Zhang | Impact IR |
Sophie Zhang | Impact IR |
Phone: (646) 893-8916 |
Email: sophie.zhang@irimpact.com |
Email: maggie.zhang@irimpact.com |
|
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(UNAUDITED) |
||||||||
|
||||||||
|
|
As of |
|
|||||
|
|
March 31, 2021 |
|
|
September 30, 2020 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
Cash |
|
$ |
1,040,607 |
|
|
$ |
53,106 |
|
Accounts receivable, net |
|
|
8,869,747 |
|
|
|
5,771,008 |
|
Inventories, net |
|
|
1,446,516 |
|
|
|
1,016,442 |
|
Advance to suppliers, net |
|
|
1,894,359 |
|
|
|
3,491,145 |
|
Deferred initial public offering costs |
|
|
984,162 |
|
|
|
510,079 |
|
Prepaid expenses and other current assets |
|
|
106,786 |
|
|
|
7,434 |
|
TOTAL CURRENT ASSETS |
|
|
14,342,177 |
|
|
|
10,840,214 |
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net |
|
|
14,590,470 |
|
|
|
14,171,963 |
|
Intangible assets, net |
|
|
144,126 |
|
|
|
140,993 |
|
Right-of-use lease assets, net |
|
|
229,532 |
|
|
|
|
|
Deferred tax assets, net |
|
|
37,032 |
|
|
|
49,059 |
|
TOTAL ASSETS |
|
$ |
29,343,337 |
|
|
$ |
25,202,229 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Short-term loans |
|
$ |
1,823,215 |
|
|
$ |
1,289,081 |
|
Current portion of long-term loans |
|
|
2,318,528 |
|
|
|
1,227,346 |
|
Third party loans |
|
|
- |
|
|
|
690,327 |
|
Accounts payable |
|
|
577,311 |
|
|
|
1,288,629 |
|
Due to related parties |
|
|
1,019,128 |
|
|
|
2,322,990 |
|
Taxes payable |
|
|
5,688,786 |
|
|
|
4,402,625 |
|
Accrued expenses and other current liabilities |
|
|
1,275,936 |
|
|
|
442,582 |
|
Finance lease liabilities, current |
|
|
148,983 |
|
|
|
33,389 |
|
Operating lease liability, current |
|
|
57,051 |
|
|
|
|
|
TOTAL CURRENT LIABILITIES |
|
$ |
12,908,938 |
|
|
$ |
11,696,969 |
|
Long-term loans |
|
|
2,106,180 |
|
|
|
2,482,251 |
|
Finance lease liabilities, noncurrent |
|
|
110,499 |
|
|
|
- |
|
Operating lease liability, noncurrent |
|
|
176,701 |
|
|
|
- |
|
TOTAL LIABILITIES |
|
|
15,302,318 |
|
|
|
14,179,220 |
|
|
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES EQUITY |
|
|
|
|
|
|
|
|
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, |
|
$ |
580 |
|
|
$ |
580 |
|
Additional paid in capital |
|
|
5,567,873 |
|
|
|
5,251,205 |
|
Statutory reserve |
|
|
579,922 |
|
|
|
579,922 |
|
Retained earnings |
|
|
7,384,071 |
|
|
|
5,072,672 |
|
Accumulated other comprehensive income (loss) |
|
|
15,421 |
|
|
|
(388,102) |
|
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY |
|
|
13,547,867 |
|
|
|
10,516,277 |
|
Non-controlling interest |
|
|
493,152 |
|
|
|
506,732 |
|
Total equity |
|
|
14,041,019 |
|
|
|
11,023,009 |
|
TOTAL LIABILITIES AND EQUITY |
|
$ |
29,343,337 |
|
|
$ |
25,202,229 |
|
|
||||||||
*Retrospectively restated for effect of 1-for-3 shares reverse split. |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME |
||||||||
(UNAUDITED) |
||||||||
|
||||||||
|
|
For the six months ended March 31, |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
|
|
|
|
|
|
|
||
REVENUE |
|
$ |
11,698,830 |
|
|
$ |
7,149,785 |
|
COST OF REVENUE |
|
|
(8,325,148) |
|
|
|
(4,597,617) |
|
GROSS PROFIT |
|
|
3,373,682 |
|
|
|
2,552,168 |
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
Selling expenses |
|
|
(52,666) |
|
|
|
(59,765) |
|
General and administrative expenses |
|
|
(679,635) |
|
|
|
(811,799) |
|
Research and development expenses |
|
|
(106,998) |
|
|
|
(128,481) |
|
Total operating expenses |
|
|
(839,299) |
|
|
|
(1,000,045) |
|
|
|
|
|
|
|
|
|
|
INCOME FROM OPERATIONS |
|
|
2,534,383 |
|
|
|
1,552,123 |
|
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSES) |
|
|
|
|
|
|
|
|
Interest income |
|
|
294 |
|
|
|
451 |
|
Interest expense |
|
|
(197,168) |
|
|
|
(172,913) |
|
Unrealized foreign transaction exchange gain (loss) |
|
|
(65,691) |
|
|
|
(4,300) |
|
Government subsidies |
|
|
446,910 |
|
|
|
332,418 |
|
Other income |
|
|
41,548 |
|
|
|
136,482 |
|
Total other income (expenses) |
|
|
225,893 |
|
|
|
292,138 |
|
|
|
|
|
|
|
|
|
|
INCOME BEFORE INCOME TAX PROVISION |
|
|
2,760,276 |
|
|
|
1,844,261 |
|
|
|
|
|
|
|
|
|
|
INCOME TAX PROVISION |
|
|
(465,077) |
|
|
|
(249,766) |
|
|
|
|
|
|
|
|
|
|
NET INCOME |
|
|
2,295,199 |
|
|
|
1,594,495 |
|
Less: net income (loss) attributable to non-controlling interest |
|
|
(16,200) |
|
|
|
61,317 |
|
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
|
|
2,311,399 |
|
|
|
1,533,178 |
|
|
|
|
|
|
|
|
|
|
OTHER COMPREHENSIVE INCOME (LOSS) |
|
|
|
|
|
|
|
|
Total foreign currency translation adjustment |
|
|
406,143 |
|
|
|
32,468 |
|
TOTAL COMPREHENSIVE INCOME |
|
|
2,701,342 |
|
|
|
1,626,963 |
|
Less: comprehensive income (loss) attributable to non-controlling |
|
|
(13,580) |
|
|
|
59,939 |
|
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON |
|
$ |
2,714,922 |
|
|
$ |
1,567,024 |
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE |
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
0.40 |
|
|
$ |
0.30 |
|
|
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE NUMBER OF SHARES |
|
|
|
|
|
|
|
|
Basic and diluted* |
|
|
5,800,000 |
|
|
|
5,166,667 |
|
* Retrospectively restated for effect of reverse split.
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(UNAUDITED) |
||||||||
|
||||||||
|
|
For the six months ended March 31, |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
|
|
|
|
|
|
|
||
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
2,295,199 |
|
|
$ |
1,594,495 |
|
Adjustments to reconcile net income to cash provided by operating |
|
|
|
|
|
|
|
|
Allowance for doubtful accounts |
|
|
6,323 |
|
|
|
23,316 |
|
Depreciation and amortization |
|
|
117,888 |
|
|
|
134,457 |
|
Deferred income tax |
|
|
13,879 |
|
|
|
(19,459) |
|
Amortization of operating lease right-of-use assets |
|
|
26,195 |
|
|
|
- |
|
Unrealized foreign currency exchange loss |
|
|
65,691 |
|
|
|
4,300 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(2,898,493) |
|
|
|
(410,656) |
|
Inventories |
|
|
(391,958) |
|
|
|
482,914 |
|
Advance to suppliers |
|
|
1,738,442 |
|
|
|
(1,787,999) |
|
Prepaid expenses and other current assets |
|
|
(99,108) |
|
|
|
17,251 |
|
Accounts payable |
|
|
(760,103) |
|
|
|
(809,818) |
|
Operating lease liabilities |
|
|
(21,975) |
|
|
|
- |
|
Taxes payable |
|
|
1,120,847 |
|
|
|
905,514 |
|
Accrued expenses and other current liabilities |
|
|
786,942 |
|
|
|
412,845 |
|
Net cash provided by operating activities |
|
|
1,999,769 |
|
|
|
547,160 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(715) |
|
|
|
(26,957) |
|
Capital expenditures on construction-in-progress |
|
|
- |
|
|
|
(403,911) |
|
Net cash used in investing activities |
|
|
(715) |
|
|
|
(430,868) |
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Proceeds from short-term loans |
|
|
943,517 |
|
|
|
601,833 |
|
Proceeds from long-term loans |
|
|
685,067 |
|
|
|
41,001 |
|
Repayment of short-term loans |
|
|
(457,729) |
|
|
|
(1,211,475) |
|
Repayment of long-term loans |
|
|
(109,382) |
|
|
|
- |
|
Proceeds from (repayment of) borrowings from related parties |
|
|
(1,391,813) |
|
|
|
393,367 |
|
Proceeds from (repayment of) third party loans |
|
|
(716,574) |
|
|
|
76,797 |
|
Principal payment from (repayment of) finance lease |
|
|
254,970 |
|
|
|
(195,863) |
|
Payment for deferred initial public offering costs |
|
|
(155,557) |
|
|
|
(42,705) |
|
Net cash used in financing activities |
|
|
(947,501) |
|
|
|
(337,045) |
|
|
|
|
|
|
|
|
|
|
Effect of changes of foreign exchange rates on cash |
|
|
(64,052) |
|
|
|
15,605 |
|
Net increase (decrease) in cash |
|
|
987,501 |
|
|
|
(205,148) |
|
Cash, beginning of year |
|
|
53,106 |
|
|
|
293,771 |
|
Cash, end of year |
|
$ |
1,040,607 |
|
|
$ |
88,623 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information |
|
|
|
|
|
|
|
|
Cash paid for interest expense |
|
$ |
215,268 |
|
|
$ |
172,913 |
|
Cash paid for income tax |
|
$ |
1,424 |
|
|
$ |
- |
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|
|
|
|
|
Amortization of share-based compensation for initial public offering |
|
$ |
316,668 |
|
|
$ |
- |
|
Right-of-use assets obtained in exchange for operating lease |
|
|
255,811 |
|
|
|
- |
|
免責(zé)聲明:
※ 以上所展示的信息來(lái)自媒體轉(zhuǎn)載或由企業(yè)自行提供,其原創(chuàng)性以及文中陳述文字和內(nèi)容未經(jīng)本網(wǎng)站證實(shí),對(duì)本文以及其中全部或者部分內(nèi)容、文字的真實(shí)性、完整性、及時(shí)性本網(wǎng)站不作任何保證或承諾,請(qǐng)讀者僅作參考,并請(qǐng)自行核實(shí)相關(guān)內(nèi)容。如果以上內(nèi)容侵犯您的版權(quán)或者非授權(quán)發(fā)布和其它問(wèn)題需要同本網(wǎng)聯(lián)系的,請(qǐng)?jiān)?0日內(nèi)進(jìn)行。
※ 有關(guān)作品版權(quán)事宜請(qǐng)聯(lián)系中國(guó)企業(yè)新聞網(wǎng):020-34333079 郵箱:cenn_gd@126.com 我們將在24小時(shí)內(nèi)審核并處理。
標(biāo)簽 :
相關(guān)網(wǎng)文
24小時(shí)熱點(diǎn)圖片
一周新聞資訊點(diǎn)擊排行
關(guān)于我們 | CENN服務(wù) | 對(duì)外合作 | 刊登廣告 | 法律聲明 | 聯(lián)系我們 | 手機(jī)版
客戶服務(wù)熱線:020-34333079、34333137 舉報(bào)電話:020-34333002 投稿郵箱:cenn_gd@126.com
版權(quán)所有:中國(guó)企業(yè)新聞網(wǎng) 運(yùn)營(yíng)商:廣州至高點(diǎn)網(wǎng)絡(luò)科技投資有限公司 地址:廣州市海珠區(qū)江燕路353號(hào)保利紅棉48棟1004